S&P Futures
4,130.75 +7.25 (+0.18%) Dow Futures
33,955.00 +21.00 (+0.06%) Nasdaq Futures
12,561.25 +45.75 (+0.37%) Russell 2000 Futures
1,967.40 +2.30 (+0.12%) Crude Oil
75.47 +1.36 (+1.84%) Gold
1,887.10 +7.60 (+0.40%)
Kinarus Therapeutics Holding AG (KNRS.SW)
Chart Events
Performance Outlook
| Previous Close | 0.0164 |
| Open | 0.0166 |
| Bid | 0.0162 x N/A |
| Ask | 0.0168 x N/A |
| Day's Range | 0.0164 - 0.0168 |
| 52 Week Range | 0.0082 - 0.0366 |
| Volume | |
| Avg. Volume | 2,716,415 |
| Market Cap | 17.54M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 107.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for KNRS.SW
Related Research
- GlobeNewswire
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
KIN001 reduced fibrotic damage of the lung in a preclinical fibrosis modelPotential as an effective oral therapy for Idiopathic Pulmonary Fibrosis (IPF)Phase 2 clinical trial in IPF patients in preparation Basel, Switzerland, January 17, 2023. Kinarus Therapeutics AG (SIX:KNRS) “Kinarus”, a Swiss clinical-stage biopharmaceutical company announced today preclinical data supporting the potential effectiveness of its lead clinical candidate, KIN001, as an oral treatment for idiopathic pulmonary fib
- GlobeNewswire
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5 Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg and Kinarus report new antiviral data of KIN001 against SARS-CoV-2 Omicron BA.2 and BA.5 subvariantsKINFAST Phase 2 trial of KIN001 in ambulatory COVID-19 patients is actively recruiting Basel, Switzerland, 6 December 2022 -- Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical com
- GlobeNewswire
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
Method-of-use-patent covers KIN001 in ophthalmic diseasesFurther strengthens already granted KIN001 US composition of matter patent Basel, Switzerland, 22 November 2022. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announced today the receipt of a Notice of Allowability from the United States Patent and Trademark Office (USPTO) for US Patent Application No. 1
